U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H12FN3
Molecular Weight 265.2856
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIPRAGLURANT

SMILES

C(#Cc1ccccn1)CCc2cn3cc(ccc3n2)F

InChI

InChIKey=LZXMUJCJAWVHPZ-UHFFFAOYSA-N
InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2

HIDE SMILES / InChI

Molecular Formula C16H12FN3
Molecular Weight 265.2856
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800026607 | https://www.ncbi.nlm.nih.gov/pubmed/27214664 | https://www.ncbi.nlm.nih.gov/pubmed/24951854

Dipraglurant (ADX48621) is a novel, potent mGluR5 negative allosteric modulator that reduced the severity of drug-induced dyskinesia in Parkinson's disease. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co-administered simultaneously in further studies. Dipraglurant might be useful in torsion dystonia treatment also. Detected adverse events are: sweating, dyskinesia, nausea, dizziness, and anxiety. One serious adverse event described as possible syncope.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.021 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
679.6 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1320.6 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1521 ng/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
858.9 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1760.6 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2009.8 ng × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.56 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.67 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.65 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIPRAGLURANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
Disc. AE: Sweating, Dyskinesia...
AEs leading to
discontinuation/dose reduction:
Sweating (1 pt)
Dyskinesia (1 pt)
Nausea (1 pt)
Dizziness (1 pt)
Anxiety (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anxiety 1 pt
Disc. AE
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
Dizziness 1 pt
Disc. AE
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
Dyskinesia 1 pt
Disc. AE
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
Nausea 1 pt
Disc. AE
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
Sweating 1 pt
Disc. AE
100 mg 3 times / day multiple, oral (unknown)
Highest studied dose
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 76
Health Status: unhealthy
Condition: Parkinson disease
Sex: M+F
Food Status: UNKNOWN
Population Size: 76
Sources:
PubMed

PubMed

TitleDatePubMed
Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
2013 Apr 1
Patents

Sample Use Guides

50 mg once daily up to 100 mg three times daily, at the start of week 4
Route of Administration: Oral
The presence of 1 mM dipraglurant the response to D2R was unaltered, both 3 and 10 mM dose-dependently reduced the increase in both firing rate and [Ca2+]i induced by quinpirole (10 mM) in Tor1a(+/Δgag) interneurons.
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:27:19 UTC 2021
Edited
by admin
on Sat Jun 26 08:27:19 UTC 2021
Record UNII
CV8JZR21A1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPRAGLURANT
INN  
INN  
Official Name English
ADX48621
Code English
ADX-48621
Code English
DIPRAGLURANT [INN]
Common Name English
6-FLUORO-2-(4-(PYRIDIN-2-YL)BUT-3-YN-1-YL)IMIDAZO(1,2-A)PYRIDINE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 485215
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
Code System Code Type Description
CAS
872363-17-2
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL2346738
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
NCI_THESAURUS
C171677
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
EPA CompTox
872363-17-2
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
FDA UNII
CV8JZR21A1
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
PUBCHEM
44557636
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
INN
9180
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
DRUG BANK
DB12733
Created by admin on Sat Jun 26 08:27:19 UTC 2021 , Edited by admin on Sat Jun 26 08:27:19 UTC 2021
PRIMARY
Related Record Type Details
TARGET->MODULATOR
Related Record Type Details
ACTIVE MOIETY